[go: up one dir, main page]

DE102007028397A1 - Cosmetic agent, useful e.g. to reduce hair loss and to promote hair growth, comprises phase transfer catalyst made from brown algae, oligomeric procyanidine, humulone and a combination product of catalyst, procyanidine and humulone - Google Patents

Cosmetic agent, useful e.g. to reduce hair loss and to promote hair growth, comprises phase transfer catalyst made from brown algae, oligomeric procyanidine, humulone and a combination product of catalyst, procyanidine and humulone Download PDF

Info

Publication number
DE102007028397A1
DE102007028397A1 DE102007028397A DE102007028397A DE102007028397A1 DE 102007028397 A1 DE102007028397 A1 DE 102007028397A1 DE 102007028397 A DE102007028397 A DE 102007028397A DE 102007028397 A DE102007028397 A DE 102007028397A DE 102007028397 A1 DE102007028397 A1 DE 102007028397A1
Authority
DE
Germany
Prior art keywords
humulone
procyanidine
phase transfer
brown algae
combination product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE102007028397A
Other languages
German (de)
Inventor
Gerhard Knapp
Toni Gradl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE102007028397A priority Critical patent/DE102007028397A1/en
Publication of DE102007028397A1 publication Critical patent/DE102007028397A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/31—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9706—Algae
    • A61K8/9711—Phaeophycota or Phaeophyta [brown algae], e.g. Fucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Kosmetisches Mittel mit einem Gehalt an:
A. mindestens einem Einsatz von Phasentransferkatalysatoren aus Braunalgen von 0,001 bis 5,0%
B. mindestens einem Einsatz von Procyanidinen (OPC) von 0,001 bis 5,0%
C. mindestens einem Einsatz von Humulon von 0,001 bis 5,0%
D. Einsatz des Kombinationsproduktes A–CCosmetic agent containing:
A. at least one use of brown algal phase-transfer catalysts from 0.001 to 5.0%
B. at least one use of procyanidines (OPC) of 0.001 to 5.0%
C. at least one use of humulone from 0.001 to 5.0%
D. Use of the combination product A-C

Figure 00000001
Figure 00000001

Description

1.0. Die Probleme bei Haarausfall, sowie dünnem und strähnigem Haar1.0. The problems with hair loss, as well thin and stringy hair

Viele Menschen, vor allem im fortgeschrittenen Lebensalter, aber auch viele jüngere sind von Haarausfall sowie dünnem, strähnigem und splissigem Haar betroffen. Oft liegen genetische und Umwelteinflüsse (insbesondere oxidativer Stress) aber auch ein fehlerhafte Haarkosmetik zu Grunde. In allen Fällen ist der Haarfollikel betroffen. Dieser Follikel, in dem das Haar ständig neu gebildet wird, hat eine hohe Proliferationsrate. Er ist eines der empfindlichsten Systeme, der auf die kleinsten endogenen und exogenen Reize mit morphologischen und biochemischen Veränderungen reagiert. Haarausfall, dünner werdendes Haar und glanzloses Haar sind die Folge.Lots People, especially in advanced age, but also many younger are from hair loss as well as thin, strands and splissigem hair affected. Often there are genetic and environmental factors (especially oxidative stress) as well a faulty hair cosmetics based. In all cases the hair follicle is affected. This follicle in which the hair is constantly re-formed, has a high proliferation rate. He is one of the most sensitive systems, the smallest endogenous and exogenous stimuli with morphological and biochemical Changes respond. Hair loss, thinning Hair and dull hair are the result.

Wie jedes stoffwechselaktive Organ braucht der Haarfollikel eine gute Durchblutung und Sauerstoffversorgung. Andererseits muss Entzündungen vorgebeugt werden. Ganz entscheidend (und häufig vernachlässigt) ist dabei die Art und Qualität des Bindegewebes in das der Follikel eingebettet ist. Bei der Betrachtung der funktionellen Einheit 'Bindegewebe' im allgemeinen und insbesondere bei der Betrachtung des Bindegewebes der Kopfhaut, der Umgebung des Haarfollikels, ist zu unterscheiden zwischen einem blutgefäss-führenden interstitiellen, einem blutgefäss-losem und einem festen Bindegewebe. Dieses Mesenchym ist die Bildungsstätte

  • (a) zellulärer Bestandteile wie der Fibroblasten, Fibrozyten, Makrophagen und Mastzellen
  • (b) der fibrillären Elemente des Kollagens, der Proteoglykane, des Elastins und der retikulären Fasern der Grundsubstanz
Like every metabolically active organ, the hair follicle needs a good circulation and oxygen supply. On the other hand, inflammation must be prevented. The type and quality of the connective tissue in which the follicle is embedded is crucial (and often neglected). When considering the functional unit 'connective tissue' in general, and in particular when considering the connective tissue of the scalp, the environment of the hair follicle, a distinction must be made between a blood vessel-leading interstitial, a blood vessel-loose and a solid connective tissue. This mesenchyme is the educational site
  • (a) cellular components such as fibroblasts, fibrocytes, macrophages and mast cells
  • (b) fibrillar elements of collagen, proteoglycans, elastin and reticular fibers of ground substance

Der Fibroblast ist eine sehr stoffwechselaktive Zelle. Er nimmt Impulse auf, speichert sie, setzt autonome Regulationsmechanismen in Tätigkeit wie eine erhöhte Mitose, Translations- und Transkription. Er antwortet so situationsgerecht auf Veränderungen in der Peripherie indem er die Biosynthese erhöht und makromolekulare Strukturen wie Kollagen und Glykosaminoglykane vermehrt sekretiert.Of the Fibroblast is a very metabolically active cell. He takes impulses stores, stores and sets autonomous regulatory mechanisms into action such as increased mitosis, translation and transcription. He responds as appropriate to changes in the situation Periphery by increasing biosynthesis and macromolecular Structures such as collagen and glycosaminoglycans increasingly secreted.

Eine häufig eher lästige Erscheinung ist die übermäßige Talgproduktion, die zu fettigem Haar führt. Sowohl die Fettsäuren des Sebums selbst als auch zu häufiges Waschen (als Folge von fettigem Haar) können zu einer Dauerreizung führen.A Often rather annoying appearance is the excessive Sebum production, which leads to greasy hair. Both the Fatty acids of the sebum itself as well too frequent Washing (as a result of greasy hair) can cause persistent irritation to lead.

2.0. Einsatz hochwirksamer pflanzlicher Wirkstoffe auf transdermalen Transportsystemen2.0. Use of highly effective herbal Active substances on transdermal transport systems

2.1 Einsatz von Phasentransferkatalysatoren aus Braunalgen2.1 Use of Phase Transfer Catalysts from brown algae

Oligomere Alginsäure, ein Blockpolymer von Guluronanen und Mannuronanen bildet zusammen mit zweiwertigen Kationen Kettenassoziate. Sie bilden einen Käfig aus 4 Molekülen. Im Zentrum dieses Käfigs liegt ein zweiwertiges Kation, welches die zwei Ketten zusammenhält und welches durch zwei kovalente und zwei nicht-kovalente Bindungen gehalten wird. Diese Bindungen rotieren. Diese Struktur ist in der Lage katalytisch Sauerstoff auf Zellen zu übertragen ( Gradl, Maurer 2000 ). Sauerstoff liegt in der umgebenden Flüssigkeit (Wasser, Plasma) in wässriger Lösung vor. Der geschwindigkeitsbestimmende Schritt der Sauerstoffversorgung ist dabei die Lösung des Sauerstoffs in der Lipidschicht der Zelle. Der Übergang wird durch Phasentransferkatalyse stark beschleunigt. Das Makromolekül heftet sich an die Zelloberfläche. Die Zielzelle bzw. das Zielorgan ist dabei abhängig von dem benutzten Zentralkation und/oder der Seitenkette der Alginsäure. Oligomeric alginic acid, a block polymer of guluronans and mannuronans, forms chain associates with divalent cations. They form a cage of 4 molecules. At the center of this cage is a divalent cation, which holds the two chains together and is held by two covalent and two noncovalent bonds. These bonds rotate. This structure is able to catalytically transfer oxygen to cells ( Gradl, Mason 2000 ). Oxygen is present in the surrounding liquid (water, plasma) in aqueous solution. The rate-determining step of the oxygen supply is the solution of the oxygen in the lipid layer of the cell. The transition is greatly accelerated by phase-transfer catalysis. The macromolecule attaches to the cell surface. The target cell or the target organ is dependent on the central cation used and / or the side chain of alginic acid.

In Makrophagen und deren Abkömmlingen wie den Langerhanszellen wird zudem ein Enzym, die NO-Synthase, induziert ( Gradl, Maurer 2000 ). Diese setzt aus Arginin NO frei. NO stellt einen überaus wichtigen Botenstoff im Körper dar. Unter anderem wirkt es als Neurotransmitter und als endothelium derived relaxing factor.In macrophages and their derivatives, such as Langerhans cells, an enzyme that induces NO synthase is also induced ( Gradl, Mason 2000 ). This releases arginine NO. NO is a very important messenger in the body. Among other things, it acts as a neurotransmitter and endothelium-derived relaxing factor.

In Fibroblasten fördert NO die Synthese von Kollagen und Glykosaminoglykan.In Fibroblasts NO promotes the synthesis of collagen and glycosaminoglycan.

2.2. Einsatz von Procyanidinen (OPC)2.2. Use of procyanidines (OPC)

Procyanidine haben zwei verschieden Wirkungen

  • – Durch Induktion der Stickstoffmonoxid (NO)-Synthase werden die Gefäße erweitert und dadurch die Durchblutung stark erhöht ( Valiance et al. 1990 ). Das NO wirkt andererseits auf die Fibrobiasten und erhöht die Synthese von Kollagen und Glykosaminoglykan ( Witte et al. 2000 ). Beides führt zu einem verjüngten Bindegewebe welches über die Steuerung des Redoxgleichgewichts in hohem Masse prooxidativem Stress entgegenwirkt. Dieser Stress ist mit eine wichtige Ursache für Haarprobleme.
  • – Procyanidine hemmen außerdem die Lipoxygenase (LOX) durch eine verminderte Leukotrienproduktion ( Holzhutter et al. 1997 ). Sie vermindern damit die übermäßige Talgproduktion ( Zouboulis et al. 2005 ).
Procyanidines have two different effects
  • - By induction of nitric oxide (NO) synthase, the vessels are dilated, thereby greatly increasing blood flow ( Valiance et al. 1990 ). The NO on the other hand acts on the fibrobiastes and increases the synthesis of collagen and glycosaminoglycan ( Witte et al. 2000 ). Both lead to a rejuvenated connective tissue which counteracts the control of the redox equilibrium to a high degree pro-oxidative stress. This stress is an important cause of hair problems.
  • Procyanidines also inhibit lipoxygenase (LOX) by decreasing leukotriene production ( Holzhutter et al. 1997 ). They reduce excessive sebum production ( Zouboulis et al. 2005 ).

2.3. Einsatz von Humulon2.3. Use of humulone

Der Bitterstoff des Hopfens, das Humulon hemmt die Cyclooxygenase (COX2) und vermindert so die Bildung von Prostaglandinen. Entzündungsprozesse werden auf diese Art und Weise vorzeitig beendet. ( Honma et al. 1998; Shimamura et al. 2001 ).The bitterness of hops, the humulone inhibits the cyclooxygenase (COX2) and thus reduces the formation of prostaglandins. Inflammatory processes are terminated prematurely in this way. ( Honma et al. 1998; Shimamura et al. 2001 ).

Ausgangspunkt zur Bildung von Prostaglandinen sowohl wie von Leukotrienen ist die Arachidonsäure.starting point for the formation of prostaglandins as well as leukotrienes the arachidonic acid.

2.4. Transdermales Transportsystem2.4. Transdermal transport system

Bei topischer Applikation ist es ein Problem die relativ großmolekularen Wirksubstanzen an den Wirkort zu bringen. Neben Mini-Emulsionen und amphiphilen Polymeren, sowie physikalischer Hilfen (Ionotophorese, Sonophorese) können hierzu auch sehr kleine Partikel (20 nm und kleiner) als Träger verwendet werden ( Gradl 2003 ). Die Effektivität des Transports ist dabei offenbar von der Kleinheit der Partikel abhängig. Im vorliegenden Fall wurden amorphe Siliziumdioxidpartikel verwendet, da deren physiologische Unbedenklichkeit seit Jahrzehnten geprüft ist.With topical application, it is a problem to bring the relatively large molecular weight active substances to the site of action. In addition to mini-emulsions and amphiphilic polymers, as well as physical aids (ionotophoresis, sonophoresis), it is also possible to use very small particles (20 nm and smaller) as support ( Gradl 2003 ). The effectiveness of the transport obviously depends on the small size of the particles. In the present case, amorphous silicon dioxide particles were used because their physiological safety has been tested for decades.

3.0. Einsatz des Kombinationsprodukts3.0. Use of the combination product

Versuche zeigten, dass eine Kombination von Humulon, OPC und Phasentransferkatalysator auf einem transdermalen Transportsystem (amorphe Siliziumdioxidpartikel) zu einem vermehrten Haarwachstum, sowie zu kräftigerem, griffigerem und glänzendem Haar führte. tries showed that a combination of humulone, OPC and phase transfer catalyst on a transdermal transport system (amorphous silicon dioxide particles) to increased hair growth, as well as to stronger, more grippy and shiny hair led.

LITERATURLITERATURE

  • 1) Gradl T, Maurer S: Macro and trace elements as central cations in phase transfer catalysts and their biological meaning. 20. Arbeitstagung Mengen- und Spurenelemente, Friedrich Schiller Universität Jena, 2000 1) Gradl T, Maurer S: Macro and trace elements as central cations in phase transfer catalysts and their biological meaning. 20th Workshop on Volume and Trace Elements, Friedrich Schiller University Jena, 2000
  • 2) Gradl T: Steuerung von Zytokinen bei Rheumatoider Arthritis durch Gewürze und Gewürzextrakte. Journal für Orthomolekulare Medizin 11(3): 42–47, 2003 2) Gradl T: Control of cytokines in rheumatoid arthritis by spices and spice extracts. Journal of Orthomolecular Medicine 11 (3): 42-47, 2003
  • 3) Holzhutter HG, R Wiesner, J Rathmann, R Stosser, H Kuhn: A kinetic model for the interaction of nitric oxide with a mammalian lipoxygenase. European Journal of Biochemistry, Vol 245: 608–616, 1997 3) Holzhutter HG, R Wiesner, J Rathmann, R Stosser, H Kuhn: A kinetic model for the interaction of nitric oxide with a mammalian lipoxygenase. European Journal of Biochemistry, Vol. 245: 608-616, 1997
  • 4) Honma Y, Tobe H, Makishima M, Yokoyama A, Okabe-Kado J: Induction of differentiation of myelogenous leukaemia cells by humulone, a bitter in the hop. Leuk Res 22(7): 605–10, 1998 4) Honma Y, Tobe H, Makishima M, Yokoyama A, Okabe-Kado J: Induction of differentiation of myelogenous leukemia cells by humulone, a bitter in the hop. Leuk Res 22 (7): 605-10, 1998
  • 5) Shimamura M, Hazato T, Ashino H, Yamamoto Y, Iwasaki E, Tobe H, Yamamoto K, Yamamoto S: Inhibition of angiogenesis by humulone, a bitter acid from beer hop. Biochem Biophys Res Commun 289(1): 220–4, 2001 5) Shimamura M, Hazato T, Ashino H, Yamamoto Y, Iwasaki E, Tobe H, Yamamoto K, Yamamoto S: Inhibition of angiogenesis by humulone, a bitter acid from beer hop. Biochem Biophys Res Commun 289 (1): 220-4, 2001
  • 6) Vallance P, Collier J, Moncada S: Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet. 22–29; 336(8730): 1589–90, 1990 6) Vallance P, Collier J, Moncada S: Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet. 22-29; 336 (8730): 1589-90, 1990
  • 7) Witte MB, Thornton FJ, Efron DT, Barbul A: Enhancement of fibroblast collagen synthesis by nitric oxide. Nitric oxide 4(6): 572–582, 2000 7) Witte MB, Thornton FJ, Efron DT, Barbul A: Enhancement of fibroblast collagen synthesis by nitric oxide. Nitric oxide 4 (6): 572-582, 2000
  • 8) Zouboulis CC, Saborowski A, Boschnalkow A: Zileuton, an oral Lipoxygenase inhibitor, directly reduces sebum production, Dermatology 210(1): 36–38, 2005 8th) Zouboulis CC, Saborowski A, Boschnalkow A: Zileuton, to oral lipoxygenase inhibitor, directly reduced sebum production, Dermatology 210 (1): 36-38, 2005

ZITATE ENTHALTEN IN DER BESCHREIBUNGQUOTES INCLUDE IN THE DESCRIPTION

Diese Liste der vom Anmelder aufgeführten Dokumente wurde automatisiert erzeugt und ist ausschließlich zur besseren Information des Lesers aufgenommen. Die Liste ist nicht Bestandteil der deutschen Patent- bzw. Gebrauchsmusteranmeldung. Das DPMA übernimmt keinerlei Haftung für etwaige Fehler oder Auslassungen.This list The documents listed by the applicant have been automated generated and is solely for better information recorded by the reader. The list is not part of the German Patent or utility model application. The DPMA takes over no liability for any errors or omissions.

Zitierte Nicht-PatentliteraturCited non-patent literature

  • - Gradl, Maurer 2000 [0005] - Gradl, Maurer 2000 [0005]
  • - Gradl, Maurer 2000 [0006] - Gradl, Maurer 2000 [0006]
  • - Valiance et al. 1990 [0008] - Valiance et al. 1990 [0008]
  • - Witte et al. 2000 [0008] - Witte et al. 2000 [0008]
  • - Holzhutter et al. 1997 [0008] Holzhutter et al. 1997 [0008]
  • - Zouboulis et al. 2005 [0008] Zouboulis et al. 2005 [0008]
  • - Honma et al. 1998; Shimamura et al. 2001 [0009] - Honma et al. 1998; Shimamura et al. 2001 [0009]
  • - Gradl 2003 [0011] - Gradl 2003 [0011]
  • - Gradl T, Maurer S: Macro and trace elements as central cations in phase transfer catalysts and their biological meaning. 20. Arbeitstagung Mengen- und Spurenelemente, Friedrich Schiller Universität Jena, 2000 [0012] - Gradl T, Maurer S: Macro and trace elements as central cations in phase transfer catalysts and their biological meaning. 20th Workshop on Volume and Trace Elements, Friedrich Schiller University Jena, 2000 [0012]
  • - Gradl T: Steuerung von Zytokinen bei Rheumatoider Arthritis durch Gewürze und Gewürzextrakte. Journal für Orthomolekulare Medizin 11(3): 42–47, 2003 [0012] - Gradl T: Control of cytokines in rheumatoid arthritis by spices and spice extracts. Journal of Orthomolecular Medicine 11 (3): 42-47, 2003 [0012]
  • - Holzhutter HG, R Wiesner, J Rathmann, R Stosser, H Kuhn: A kinetic model for the interaction of nitric oxide with a mammalian lipoxygenase. European Journal of Biochemistry, Vol 245: 608–616, 1997 [0012] Holzhutter HG, R Wiesner, J Rathmann, R. Stosser, H. Kuhn: A kinetic model for the interaction of nitric oxide with a mammalian lipoxygenase. European Journal of Biochemistry, Vol 245: 608-616, 1997 [0012]
  • - Honma Y, Tobe H, Makishima M, Yokoyama A, Okabe-Kado J: Induction of differentiation of myelogenous leukaemia cells by humulone, a bitter in the hop. Leuk Res 22(7): 605–10, 1998 [0012] - Honma Y, Tobe H, Makishima M, Yokoyama A, Okabe-Kado J: Induction of differentiation of myelogenous leukemia cells by humulone, a bitter in the hop. Leuk Res 22 (7): 605-10, 1998 [0012]
  • - Shimamura M, Hazato T, Ashino H, Yamamoto Y, Iwasaki E, Tobe H, Yamamoto K, Yamamoto S: Inhibition of angiogenesis by humulone, a bitter acid from beer hop. Biochem Biophys Res Commun 289(1): 220–4, 2001 [0012] - Shimamura M, Hazato T, Ashino H, Yamamoto Y, Iwasaki E, Tobe H, Yamamoto K, Yamamoto S: Inhibition of angiogenesis by humulone, a bitter acid from beer hop. Biochem Biophys Res Commun 289 (1): 220-4, 2001 [0012]
  • - Vallance P, Collier J, Moncada S: Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet. 22–29; 336(8730): 1589–90, 1990 [0012] - Vallance P, Collier J, Moncada S: Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet. 22-29; 336 (8730): 1589-90, 1990 [0012]
  • - Witte MB, Thornton FJ, Efron DT, Barbul A: Enhancement of fibroblast collagen synthesis by nitric oxide. Nitric oxide 4(6): 572–582, 2000 [0012] - Witte MB, Thornton FJ, Efron DT, Barbul A: Enhancement of fibroblast collagen synthesis by nitric oxide. Nitric oxide 4 (6): 572-582, 2000 [0012]
  • - Zouboulis CC, Saborowski A, Boschnalkow A: Zileuton, an oral Lipoxygenase inhibitor, directly reduces sebum production, Dermatology 210(1): 36–38, 2005 [0012] Zouboulis CC, Saborowski A, Boschnalkow A: Zileuton, an oral lipoxygenase inhibitor, directly reduced sebum production, Dermatology 210 (1): 36-38, 2005 [0012]

Claims (7)

Kosmetisches Mittel mit einem Gehalt an: A. mindestens einem Einsatz von Phasentransferkatalysatoren aus Braunalgen von 0,001 bis 5,0% B. mindestens einem Einsatz von Procyanidinen (OPC) von 0,001 bis 5,0% C. mindestens einem Einsatz von Humulon von 0,001 bis 5,0% D. Einsatz des Kombinationsproduktes A–CCosmetic agent containing: A. at least one use of phase-transfer catalysts from brown algae from 0.001 to 5.0% B. at least one use of procyanidins (OPC) from 0.001 to 5.0% C. at least one use of humulone from 0.001 to 5.0% D. Use of the combination product A-C Mittel nach Anspruch 1, dadurch gekennzeichnet, dass der Einsatz von Humulon, OPC und Phasentransferkatalysator auf einem transdermalen Transportsystem (amorphe Sliziumdioxidpartikel) zu einem vermehrten und neuem Haarwachstum, sowie zu kräftigerem, griffigerem und glänzenden Haar führt.Means according to claim 1, characterized in that the use of humulone, OPC and phase transfer catalyst on one Transdermal transport system (amorphous silicon dioxide particles) to a increased and new hair growth, as well as to stronger, better grip and shiny hair leads. Mittel nach Anspruch 2, dadurch gekennzeichnet, dass es mindestens eine durchblutungsfördernde Substanz enthält.Means according to claim 2, characterized in that it contains at least one circulation-promoting substance. Mittel nach vorhergehenden Ansprüchen, dadurch gekennzeichnet, dass die durchblutungsfördernde Substanz ausgewählt ist aus Trimethylxanthin (Coffein), Menthol, Kampher und durchblutungsfördernden Pflanzenextrakten.Agent according to the preceding claims, characterized characterized in that the circulation-promoting substance is selected from trimethylxanthine (caffeine), menthol, Camphor and circulation-promoting plant extracts. Mittel nach einem der vorgehenden Ansprüchen, dadurch gekennzeichnet, dass es in Form eines Kopfhauttonikums vorliegt.Means according to one of the preceding claims, characterized in that it is in the form of a scalp tonic. Verwendung einer Kombination aus: Phasentransferkatalysatoren aus Braunalgen, Procyanidinen und Humulon sowie aus durchblutungsfördernden Substanzen.Using a combination of: Phase transfer catalysts from brown algae, procyanidines and humulone as well as from circulation-promoting Substances. Kosmetisches Verfahren zur Reduzierung von Haarausfall, wobei der Wirkstoffkomplex gemäß Anspruch 1 auf die Kopfhaut aufgetragen wird.Cosmetic procedure to reduce hair loss, wherein the active ingredient complex according to claim 1 the scalp is applied.
DE102007028397A 2007-06-15 2007-06-15 Cosmetic agent, useful e.g. to reduce hair loss and to promote hair growth, comprises phase transfer catalyst made from brown algae, oligomeric procyanidine, humulone and a combination product of catalyst, procyanidine and humulone Ceased DE102007028397A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE102007028397A DE102007028397A1 (en) 2007-06-15 2007-06-15 Cosmetic agent, useful e.g. to reduce hair loss and to promote hair growth, comprises phase transfer catalyst made from brown algae, oligomeric procyanidine, humulone and a combination product of catalyst, procyanidine and humulone

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007028397A DE102007028397A1 (en) 2007-06-15 2007-06-15 Cosmetic agent, useful e.g. to reduce hair loss and to promote hair growth, comprises phase transfer catalyst made from brown algae, oligomeric procyanidine, humulone and a combination product of catalyst, procyanidine and humulone

Publications (1)

Publication Number Publication Date
DE102007028397A1 true DE102007028397A1 (en) 2008-12-18

Family

ID=39986253

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102007028397A Ceased DE102007028397A1 (en) 2007-06-15 2007-06-15 Cosmetic agent, useful e.g. to reduce hair loss and to promote hair growth, comprises phase transfer catalyst made from brown algae, oligomeric procyanidine, humulone and a combination product of catalyst, procyanidine and humulone

Country Status (1)

Country Link
DE (1) DE102007028397A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106854383A (en) * 2015-12-09 2017-06-16 中国科学院生物物理研究所 Natural pigments for black hair and compositions thereof
CN111840115A (en) * 2020-08-17 2020-10-30 蓝科恒业医疗科技(长春)有限公司 Procyanidine oligomer-based facial hormone-dependent dermatitis treatment liquid and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05170625A (en) * 1991-12-24 1993-07-09 Kanebo Ltd Hair tonic
JP2002037715A (en) * 2000-07-24 2002-02-06 Fancl Corp Hair restorer
EP1402874A1 (en) * 2001-06-01 2004-03-31 Masaya Tanaka Acidic composition for external use and agent for accelerating infiltration of cosmetic preparation, hair-growing agent, and preparation for external use each containing the composition into skin or the like
US20070036742A1 (en) * 2005-08-09 2007-02-15 Access Business Group International Llc Methods and compositions for modulating hair growth or regrowth

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05170625A (en) * 1991-12-24 1993-07-09 Kanebo Ltd Hair tonic
JP2002037715A (en) * 2000-07-24 2002-02-06 Fancl Corp Hair restorer
EP1402874A1 (en) * 2001-06-01 2004-03-31 Masaya Tanaka Acidic composition for external use and agent for accelerating infiltration of cosmetic preparation, hair-growing agent, and preparation for external use each containing the composition into skin or the like
US20070036742A1 (en) * 2005-08-09 2007-02-15 Access Business Group International Llc Methods and compositions for modulating hair growth or regrowth

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
ChironMed [online], 2005 [recherchiert am 14.03. 2008], Im Internet: <URL: http://www.chironmed.de/ artikelueber.php?wgruppeid=46&wgruppe_offen=46& wgruppenname=Biomum%20T&sid=d96c3056d4d3abca1ae615 a50289a61f>
ChironMed [online], 2005 [recherchiert am 14.03. 2008], Im Internet: <URL: http://www.chironmed.de/ artikelueber.php?wgruppeid=46&wgruppe_offen=46&wgruppenname=Biomum%20T&sid=d96c3056d4d3abca1ae615 a50289a61f> *
Gradl T, Maurer S: Macro and trace elements as central cations in phase transfer catalysts and their biological meaning. 20. Arbeitstagung Mengen- und Spurenelemente, Friedrich Schiller Universität Jena, 2000
Gradl T: Steuerung von Zytokinen bei Rheumatoider Arthritis durch Gewürze und Gewürzextrakte. Journal für Orthomolekulare Medizin 11(3): 42-47, 2003
Holzhutter HG, R Wiesner, J Rathmann, R Stosser, H Kuhn: A kinetic model for the interaction of nitric oxide with a mammalian lipoxygenase. European Journal of Biochemistry, Vol 245: 608-616, 1997
Honma Y, Tobe H, Makishima M, Yokoyama A, Okabe-Kado J: Induction of differentiation of myelogenous leukaemia cells by humulone, a bitter in the hop. Leuk Res 22(7): 605-10, 1998
KELLY, G., GRADL, T.: Einsatz einer Nahrungser- gänzung bei Allergien vom Soforttyp. 2007, <URL: http://www.dr-gerd-kelly.de>
KELLY, G., GRADL, T.: Einsatz einer Nahrungsergänzung bei Allergien vom Soforttyp. 2007, <URL: http://www.dr-gerd-kelly.de> *
Shimamura M, Hazato T, Ashino H, Yamamoto Y, Iwasaki E, Tobe H, Yamamoto K, Yamamoto S: Inhibition of angiogenesis by humulone, a bitter acid from beer hop. Biochem Biophys Res Commun 289(1): 220-4, 2001
Vallance P, Collier J, Moncada S: Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet. 22-29; 336(8730): 1589-90, 1990
Witte MB, Thornton FJ, Efron DT, Barbul A: Enhancement of fibroblast collagen synthesis by nitric oxide. Nitric oxide 4(6): 572-582, 2000
Zouboulis CC, Saborowski A, Boschnalkow A: Zileuton, an oral Lipoxygenase inhibitor, directly reduces sebum production, Dermatology 210(1): 36-38, 2005

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106854383A (en) * 2015-12-09 2017-06-16 中国科学院生物物理研究所 Natural pigments for black hair and compositions thereof
CN106854383B (en) * 2015-12-09 2019-12-20 中国科学院生物物理研究所 Natural pigment for dyeing black hair and composition thereof
CN111840115A (en) * 2020-08-17 2020-10-30 蓝科恒业医疗科技(长春)有限公司 Procyanidine oligomer-based facial hormone-dependent dermatitis treatment liquid and preparation method thereof

Similar Documents

Publication Publication Date Title
Bedran-Russo et al. Mechanical properties of tannic-acid-treated dentin matrix
Esposito et al. Design and characterization of sodium alginate and poly (vinyl) alcohol hydrogels for enhanced skin delivery of quercetin
Cefali et al. Flavonoid-enriched plant-extract-loaded emulsion: a novel phytocosmetic sunscreen formulation with antioxidant properties
EP2869854B1 (en) Composition containing ecotine or hydroxyecotine as an active substances for promoting the regeneration of injured body tissue
Szél et al. Anti‐irritant and anti‐inflammatory effects of glycerol and xylitol in sodium lauryl sulphate‐induced acute irritation
Morganti et al. Green nanotechnology serving the bioeconomy: Natural beauty masks to save the environment
DE102008059523A1 (en) Cosmetic mixture containing ascorbic acid-2-glucoside and ergothioneine
Saewan Effect of coffee berry extract on anti-aging for skin and hair—In vitro approach
CN110090190B (en) Soothing cooling liquid for baby plants and preparation method thereof
Alsareii et al. Enhanced in vivo wound healing efficacy of a novel piperine-containing bioactive hydrogel in excision wound rat model
RU2572505C2 (en) COMPOSITIONS CONTAINING NFkB-INHIBITOR AND TROPOELASTIN PROMOTER
DE69807097T2 (en) ACTIVE SYNERGISTIC COMPLEX AND COSMETIC AND / OR PHARMACEUTICAL PRODUCT THAT CONTAINS THIS COMPLEX
CN108670878A (en) The cosmetic composition of anti-skin allergy
Ulger et al. Comparing the effects of nebivolol and dexpanthenol on wound healing: an experimental study
Martins et al. Skin penetration and photoprotection of topical formulations containing benzophenone-3 solid lipid microparticles prepared by the solvent-free spray-congealing technique
Kotian et al. Nanocrystal-based topical gels for improving wound healing efficacy of curcumin
Garcia-Bilbao et al. Preparation, characterization, and biological evaluation of retinyl palmitate and Dead Sea water loaded nanoemulsions toward topical treatment of skin diseases
Kardan et al. Polyethylene glycol–based nanocerium improves healing responses in excisional and incisional wound models in rats
CN118119374A (en) Fruit-derived vesicles and cosmetic compositions comprising the same
Gundogdu et al. The evaluation of the effects of nanoemulsion formulations containing boron and/or zinc on the wound healing in diabetic rats
Pawłowicz et al. Towards the Preparation of a Hydrogel from Lyophilisates of the Aloe arborescens Aqueous Extract
CN109316368A (en) Anti-aging skin care product and preparation method thereof
Ojeda-Martínez et al. Skin wound healing with chitosan thin films containing supported silver nanospheres
Agarwal et al. Evaluating the effects of nacre on human skin and scar cells in culture
Kuzucu Extremophilic solutions: the role of deinoxanthin in counteracting UV-induced skin harm

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
8122 Nonbinding interest in granting licences declared
8131 Rejection